Daily Newsletter

11 August 2023

Daily Newsletter

11 August 2023

Telix doses first Chinese patient in prostate cancer imaging study

The study will enrol up to 110 patients who have biochemically recurrent prostate cancer.

RanjithKumar Dharma August 11 2023

Telix has dosed the first Chinese patient in the pivotal Phase III registration trial of TLX591-CDx (Illuccix), a kit designed to prepare 68Ga-PSMA-11 for PET imaging of prostate cancer.

The Phase III open-label, single-arm, prospective multicenter Illuccix China study is conducted in patients with biochemically recurrent (BCR) prostate cancer.

It is intended to serve as a bridge to the marketing authorisation granted by the US Food and Drug Administration to Illuccix.

In collaboration with Telix's strategic partner for the Greater China region, Grand Pharmaceutical Group, the study aims to demonstrate that the diagnostic utility of TLX591-CDx is compatible with both Chinese and Western populations.

The trial will enrol a maximum of 110 patients who have BCR prostate cancer.

The collected data will be used to support an application for marketing authorisation of TLX591-CDx in China in the future.

Telix Asia-Pacific regional medical director Dr Shams UL Arifeen said: “We are pleased to have commenced this study, which brings advanced PSMA-PET imaging one step closer for Chinese men with prostate cancer.

“With our strategic collaborator in the region, Grand Pharma, we would like to express our gratitude to Dr Yong He, principal investigator at Zhongnan Hospital of Wuhan University as well as his clinical research team, and the patients who will contribute to this important study.”

Healthcare companies are hesitant to invest in the metaverse

The COVID-19 pandemic pushed the healthcare industry to rapid digitalization. Increased use of telehealth, telepresence systems, remote diagnostics, predictive AI, and wearable technology is changing how healthcare is delivered and improving patient outcomes. Emerging technologies such as AR and VR are becoming increasingly routine for professional training, surgical assistance, and treatment of psychological and neurological disorders. In the pharma and medical devices industries, AR, VR, and AI are rapidly accelerating drug discovery and manufacturing and generating supply chain efficiencies. New digital opportunities will look to build upon disruptive technologies. However, affordability is a limiting factor to widespread adoption. Per GlobalData estimates, the metaverse market is expected to grow at a CAGR of more than 33% between 2023 and 2030. Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.

Newsletters by sectors


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.